Physiologically based pharmacokinetic modelling
Physiologically based pharmacokinetic (PBPK) modeling is a mathematical modeling technique for predicting the absorption, distribution, metabolism and excretion (ADME) of synthetic or natural chemical substances in humans and other animal species. PBPK modeling is used in pharmaceutical research and drug development, and in health risk assessment for cosmetics or general chemicals.
PBPK models strive to be mechanistic by mathematically transcribing anatomical, physiological, physical, and chemical descriptions of the phenomena involved in the complex ADME processes. A large degree of residual simplification and empiricism is still present in those models, but they have an extended domain of applicability compared to that of classical, empirical function based, pharmacokinetic models. PBPK models may have purely predictive uses, but other uses, such as statistical inference, have been made possible by the development of Bayesian statistical tools able to deal with complex models. That is true for both toxicity risk assessment and therapeutic drug development.
PBPK models try to rely a priori on the anatomical and physiological structure of the body, and to a certain extent, on biochemistry. They are usually multi-compartment models, with compartments corresponding to predefined organs or tissues, with interconnections corresponding to blood or lymph flows (more rarely to diffusions). A system of differential equations for concentration or quantity of substance on each compartment can be written, and its parameters represent blood flows, pulmonary ventilation rate, organ volumes etc., for which information is available in scientific publications. Indeed the description they make of the body is simplified and a balance needs to be struck between complexity and simplicity. Besides the advantage of allowing the recruitment of a priori information about parameter values, these models also facilitate inter-species transpositions or extrapolation from one mode of administration to another (e.g., inhalation to oral). An example of a 7-compartment PBTK model, suitable to describe the fate of many solvents in the mammalian body, is given in the Figure on the right.
- 1 History
- 2 Building a PBPK model
- 3 Uses of PBPK modeling
- 4 Limits and extensions of PBPK modelling
- 5 References
- 6 Forums
- 7 Software
The first pharmacokinetic model described in the scientific literature  was in fact a PBPK model. It led, however, to computations intractable at that time. The focus shifted then to simpler models , for which analytical solutions could be obtained (such solutions were sums of exponential terms, which led to further simplifications.) The availability of computers and numerical integration algorithms marked a renewed interest in physiological models in the early 1970s. For substances with complex kinetics, or when inter-species extrapolations were required, simple models were insufficient and research continued on physiological models   . By 2010, hundreds of scientific publications have described and used PBPK models, and at least two private companies are basing their business on their expertise in this area.
Building a PBPK model
The model equations follow the principles of mass transport, fluid dynamics, and biochemistry in order to simulate the fate of a substance in the body . Compartments are usually defined by grouping organs or tissues with similar blood perfusion rate and lipid content (i.e. organs for which chemicals' concentration vs. time profiles will be similar). Ports of entry (lung, skin, intestinal tract...), ports of exit (kidney, liver...) and target organs for therapeutic effect or toxicity are often left separate. Bone can be excluded from the model if the substance of interest does not distribute to it. Connections between compartment follow physiology (e.g., blood flow in exit of the gut goes to liver, etc.)
Basic transport equations
Drug distribution into a tissue can be rate-limited by either perfusion or permeability. Perfusion-rate-limited kinetics apply when the tissue membranes present no barrier to diffusion. Blood flow, assuming that the drug is transported mainly by blood, as is often the case, is then the limiting factor to distribution in the various cells of the body. That is usually true for small lipophilic drugs. Under perfusion limitation, the instantaneous rate of entry for the quantity of drug in a compartment is simply equal to (blood) volumetric flow rate through the organ times the incoming blood concentration. In that case; for a generic compartment i, the differential equation for the quantity Qi of substance, which defines the rate of change in this quantity, is:
where Fi is blood flow (noted Q in the Figure above), Cart incoming arterial blood concentration, Pi the tissue over blood partition coefficient and Vi the volume of compartment i.
A complete set of differential equations for the 7-compartment model shown above could therefore be:
Poorly-perfused tissues (muscle and skin):
Heart and lung:
The above equations include only transport terms and do not account for inputs or outputs. Those can be modelled with specific terms, as in the following.
Modelling inputs is necessary to come up with a meaningful description of a chemical's pharmacokinetics. The following examples show how to write the corresponding equations.
When dealing with a bolus dose (e.g. ingestion of a tablet), first order absorption is a very common assumption. In that case the gut equation is augmented with an input term, with an absorption rate constant Ka:
That requires defining an equation for the quantity ingested and present in the gut lumen:
In the absence of a gut compartment, input can be made directly in the liver. However, in that case local metabolism in the gut may not be correctly described. The case of approximately continuous absorption (e.g. via drinking water) can be modelled by a zero-order absorption rate (here Ring in units of mass over time):
More sophisticated gut absorption model can be used. In those models, additional compartments describe the various sections of the gut lumen and tissue. Intestinal pH, transit times and presence of active transporters can be taken into account .
The absorption of a chemical deposited on skin can also be modelled using first order terms. It is best in that case to separate the skin from the other tissues.
Skin absorption is quite complex in fact (to be added)...
Intravenous injection is a common clinical route of administration. (to be completed)
Inhalation occurs through the lung and is hardly dissociable from exhalation (to be completed)
... (to be added)
There are several ways metabolism can be modeled. For some models, a linear excretion rate is preferred. This can be accomplished with a simple differential equation. Otherwise a Michaelis-Menten equation, as follows, is generally appropriate for a more accurate result.
Uses of PBPK modeling
PBPK models are compartmental models like many others, but they have a few advantages over so-called "classical" pharmacokinetic models, which are less grounded in physiology. PBPK models can first be used to abstract and eventually reconcile disparate data (from physico-chemical or biochemical experiments, in vitro or in vivo pharmacological or toxicological experiments, etc.) They give also access to internal body concentrations of chemicals or their metabolites, and in particular at the site of their effects, be it therapeutic or toxic. Finally they also help interpolation and extrapolation of knowledge between:
- Doses: e.g., from the high concentrations typically used in laboratory experiments to those found in the environment
<here show a Figure with time courses at different doses and explain>
- Exposure duration: e.g., from continuous to discontinuous, or single to multiple exposures
- Routes of administration: e.g., from inhalation exposures to ingestion
- Species: e.g., transpositions from rodents to human, prior to giving a drug for the first time to subjects of a clinical trial, or when experiments on humans are deemed unethical, such as when the compound is toxic without therapeutic benefit
- Individuals: e.g., from males to females, from adults to children, from non-pregnant women to pregnant
- From in vitro to in vivo.
Some of these extrapolations are "parametric" : only changes in input or parameter values are needed to achieve the extrapolation (this is usually the case for dose and time extrapolations). Others are "nonparametric" in the sense that a change in the model structure itself is needed (e.g., when extrapolating to a pregnant female, equations for the foetus should be added).
Owing to the mechanistic basis of PBPK models, another potential use of PBPK modeling is hypothesis testing. For example, if a drug compound showed lower-than-expected oral bioavailability, various model structures (i.e., hypotheses) and parameter values can be evaluated to determine which models and/or parameters provide the best fit to the observed data. If the hypothesis that metabolism in the intestines was responsibility for the low bioavailability yielded the best fit, then the PBPK modeling results support this hypothesis over the other hypotheses evaluated.
As such, PBPK modeling can be used, inter alia, to evaluate the involvement of carrier-mediated transport, clearance saturation, enterohepatic recirculation of the parent compound, extra-hepatic/extra-gut elimination; higher in vivo solubility than predicted in vitro; drug-induced gastric emptying delays; gut loss and regional variation in gut absorption.
Limits and extensions of PBPK modelling
Each type of modelling technique has its strengths and limitations. PBPK modelling is no exception. One limitation is the potential for a large number of parameters, some of which may be correlated. This can lead to the issues of parameter identifiability and redundancy.
After numerical values are assigned to each PBPK model parameter, specialized or general computer software is typically used to numerically integrate a set of ordinary differential equations like those described above, in order to calculate the numerical value of each compartment at specified values of time (see Software). However, if such equations involve only linear functions of each compartmental value, or under limiting conditions (e.g., when input values remain very small) that guarantee such linearity is closely approximated, such equations may be solved analytically to yield explicit equations (or, under those limiting conditions, very accurate approximations) for the time-weighted average (TWA) value of each compartment as a function of the TWA value of each specified input (see, e.g., ).
PBPK models can rely on chemical property prediction models (QSAR models or predictive chemistry models) on one hand. For example, QSAR models can be used to estimate partition coefficients. They also extend into, but are not destined to supplant, systems biology models of metabolic pathways. They are also parallel to physiome models, but do not aim at modelling physiological functions beyond fluid circulation in detail. In fact the above four types of models can reinforce each other when integrated.
- Gelman, A.; Bois, F.Y.; Jiang, J. (1996). "Physiological pharmacokinetic analysis using population modeling and informative prior distributions". Journal of the American Statistical Association 91: 1400–1412. doi:10.1080/01621459.1996.10476708.
- Teorell, T. (1937). "Kinetics of distribution of substances administered to the body". Archives Internationales de Pharmacodynamie et de Thérapie 57: 205–240.
- Gibaldi M., and Perrier D. (1982). Pharmacokinetics, , Second Edition, revised and expanded ed. New-York: Marcel Dekker.
- Bischoff, K.B.; Dedrick, R.L.; Zaharko, D.S.; Longstreth, J.A. (1971). "Methotrexate pharmacokinetics". Journal of Pharmaceutical Sciences 60: 1128–1133. doi:10.1002/jps.2600600803.
- Dedrick, R.L.; Forrester, D.D., Cannon, J.N., El Dareer, S.M., Mellett, L.B. (1973). "Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species". Biochemical Pharmacology 22: 2405–2417. doi:10.1016/0006-2952(73)90342-0.
- Gerlowski, L.E.; Jain, R.K. (1983). "Physiologically based pharmacokinetic modeling: principles and applications". Journal of Pharmaceutical Sciences 72: 1103–1127. doi:10.1002/jps.2600721003.
- Droz, P.O.; Guillemin, M. P. (1983). "Human styrene exposure - V. Development of a model for biological monitoring". International Archives of Occupational and Environmental Health 53: 19–36. doi:10.1007/bf00406174.
- Lutz, R.J.; Dedrick, R.L.; Tuey, D.; Sipes, G.; Anderson, M.W.; Matthews, H.B. (1984). "Comparison of the pharmacokinetics of several polychlorinated biphenyls in mouse, rat, dog, and monkey by means of a physiological pharmacokinetic model". Drug Metabolism and Disposition 12: 527–535.
- Campbell, JL, Jr.; Clewell RA, Gentry PR, Andersen ME, Clewell HJ, III (2012). "Physiologically based pharmacokinetic/toxicokinetic modeling". Computational Toxicology, Methods in Molecular Biology Series: 439–499.
- Darwich, AS; Pade D; Ammori BJ; Jamei M; Ashcroft DM; Rostami-Hodjegan A (2012). "A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution". Journal of Pharmacy and Pharmacology.
- Bouvier d'Yvoire, M.; Prieto P., Blaauboer B.J., Bois F., Boobis A., Brochot C., Coecke S., Freidig A., Gundert-Remy U., Hartung T., Jacobs M. N., Lavé T., Leahy D.E., Lennernäs H., Loizou G.D., Meek B., Pease C., Rowland M., Spendiff M., Yang J., Zeilmaker M. (2007). "Physiologically-based kinetic modelling (PBK modelling): meeting the 3Rs agenda - The report and recommendations of ECVAM Workshop 63a". Alternatives to Laboratory Animals 35: 661–671.
- Peters, SA (2008). "Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis". Clin Pharmacokinet 47 (4): 261–75. doi:10.2165/00003088-200847040-00004. PMID 18336055.
- Bogen, K.T. (1988). "Pharmacokinetics for regulatory risk analysis: The case of trichloroethylene". Regulatory Toxicology and Pharmacology 8: 447–466. doi:10.1016/0273-2300(88)90045-1.
- Bogen, K.T.; Hall, L.C. (1989). "Pharmacokinetics for regulatory risk analysis: The case of 1,1,1-trichloroethane (methyl chloroform)". Regulatory Toxicology and Pharmacology 10: 26–50. doi:10.1016/0273-2300(89)90011-1.
- Bois, F.Y. (2009). "Physiologically-based modelling and prediction of drug interactions". Basic and Clinical Pharmacology and Toxicology 106: 154–161. doi:10.1111/j.1742-7843.2009.00488.x.
- Balant LP (1990). "Physiological pharmacokinetic modelling". Xenobiotica 20: 1241–1257. doi:10.3109/00498259009046841.
- Bois FY, Jamei M, Clewell HJ (2010). "PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals". Toxicology 278: 256–267. doi:10.1016/j.tox.2010.06.007.
- Menzel DB (1987). "Physiological pharmacokinetic modeling". Environmental Science and Technology 21: 944–950. doi:10.1021/es50001a004.
- Ramsey JC, Andersen M (1984). "A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans". Toxicology and Applied Pharmacology 73: 159–175. doi:10.1016/0041-008x(84)90064-4.
- Reddy M. et al. (2005) Physiologically Based Pharmacokinetic Modeling : Science and Applications, Wiley-Interscience.
- Peters S.A (2012) Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations, Wiley.
- Ecotoxmodels is a website on mathematical models in ecotoxicology.